Trial watch: Tumor-targeting monoclonal antibodies for oncological indications

References

• Alkan SS. Monoclonal antibodies: the story of a discovery that revolutionized science and medicine. Nat Rev Immunol 2004; 4:153-6; PMID:15040588; http://dx.doi.org/10.1038/nri1265
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27; PMID:20414205; http://dx.doi.org/10.1038/nri2744
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27297; PMID:24701370; http://dx.doi.org/10.4161/onci.27297
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kroemer G, Eggermont A. Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology 2014; 3: in press
   Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; PMID:23482847; http://dx.doi.org/10.4161/onci.22789
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27048; PMID:24605265; http://dx.doi.org/10.4161/onci.27048
   PubMed Web of Science ®Google Scholar
• Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH, Navale L, Amado RG, Schwab G, Figlin RA. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 2008; 14:502-8; PMID:18223225; http://dx.doi.org/10.1158/1078-0432.CCR-07-1509
   PubMed Web of Science ®Google Scholar
• Ming Lim C, Stephenson R, Salazar AM, Ferris RL. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR head and neck cancer cells. Oncoimmunology 2013; 2:e24677; PMID:23894722; http://dx.doi.org/10.4161/onci.24677
   PubMedGoogle Scholar
• Kaplan-Lefko PJ, Graves JD, Zoog SJ, Pan Y, Wall J, Branstetter DG, Moriguchi J, Coxon A, Huard JN, Xu R et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther 2010; 9:618-31; PMID:20150762; http://dx.doi.org/10.4161/cbt.9.8.11264
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 2006; 24:19-28; PMID:16413920; http://dx.doi.org/10.1016/j.immuni.2005.11.010
   PubMed Web of Science ®Google Scholar
• Hubert P, Amigorena S. Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy. Oncoimmunology 2012; 1:103-5; PMID:22720225; http://dx.doi.org/10.4161/onci.1.1.17963
   PubMed Web of Science ®Google Scholar
• Houot R, Kohrt H, Levy R. Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. Oncoimmunology 2012; 1:957-8; PMID:23162770; http://dx.doi.org/10.4161/onci.19974
   PubMed Web of Science ®Google Scholar
• Kute T, Stehle Jr JR, Ornelles D, Walker N, Delbono O, Vaughn JP. Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells. Oncoimmunology 2012; 1:810-21; PMID:23162748; http://dx.doi.org/10.4161/onci.20447
   PubMed Web of Science ®Google Scholar
• Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci 2011; 16:277-306; PMID:21196171; http://dx.doi.org/10.2741/3688
   PubMed Web of Science ®Google Scholar
• Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res 2010; 20:34-50; PMID:20010915; http://dx.doi.org/10.1038/cr.2009.139
   PubMed Web of Science ®Google Scholar
• Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9:729-40; PMID:19730437; http://dx.doi.org/10.1038/nri2620
   PubMed Web of Science ®Google Scholar
• Seimetz D. Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). J Cancer 2011; 2:309-16; PMID:21716847; http://dx.doi.org/10.7150/jca.2.309
   PubMed Web of Science ®Google Scholar
• Armeanu-Ebinger S, Hoh A, Wenz J, Fuchs J. Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma. Oncoimmunology 2013; 2:e22620; PMID:23482411; http://dx.doi.org/10.4161/onci.22620
   PubMedGoogle Scholar
• Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-63; PMID:12011122; http://dx.doi.org/10.1200/JCO.2002.11.076
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96:1259-66; PMID:10942366
   PubMed Web of Science ®Google Scholar
• Hughes B. Antibody-drug conjugates for cancer: poised to deliver? Nat Rev Drug Discov 2010; 9:665-7; PMID:20811367; http://dx.doi.org/10.1038/nrd3270
   PubMed Web of Science ®Google Scholar
• Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, Shah DK, Haddish-Berhane N, Kabbarah O. Antibody-drug conjugates: an emerging modality for the treatment of cancer. Ann N Y Acad Sci 2014; 1321:41-54; PMID:25123209; http://dx.doi.org/10.1111/nyas.12499
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391-400; PMID:15136787; http://dx.doi.org/10.1038/nrd1381
   PubMed Web of Science ®Google Scholar
• Michielsen AJ, Ryan EJ, O'Sullivan JN. Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment. Oncoimmunology 2012; 1:1445-7; PMID:23243624; http://dx.doi.org/10.4161/onci.21318
   PubMed Web of Science ®Google Scholar
• de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, Lazar V, Dessen P, Harper F et al. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 2007; 67:6253-62; PMID:17616683; http://dx.doi.org/10.1158/0008-5472.CAN-07-0538
   PubMed Web of Science ®Google Scholar
• Goldberg RM. Cetuximab. Nat Rev Drug Discov 2005; Suppl:S10-11; Available: http://www.ncbi.nlm.nih.gov/pubmed/?term=Goldberg+RM.+Cetuximab.+Nat+Rev+Drug+Discov+2005%3B+Suppl%3AS10-1; PMID:15962524; http://dx.doi.org/10.1038/nrd1728
   PubMedGoogle Scholar
• Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007; 120:781-7; PMID:17096332; http://dx.doi.org/10.1002/ijc.22370
   PubMed Web of Science ®Google Scholar
• Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, López-Albaitero A, Gibson SP, Gooding WE, Ferrone S et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 2013; 19:1858-72; PMID:23444227; http://dx.doi.org/10.1158/1078-0432.CCR-12-2426
   PubMed Web of Science ®Google Scholar
• Derer S, Lohse S, Valerius T. EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies. Oncoimmunology 2013; 2:e24052; PMID:23762793; http://dx.doi.org/10.4161/onci.24052
   PubMedGoogle Scholar
• Choi BD, Gedeon PC, Sanchez-Perez L, Bigner DD, Sampson JH. Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. Oncoimmunology 2013; 2:e26757; PMID:24475376; http://dx.doi.org/10.4161/onci.26757
   PubMed Web of Science ®Google Scholar
• Choi BD, Pastan I, Bigner DD, Sampson JH. A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system. Oncoimmunology 2013; 2:e23639; PMID:23734318; http://dx.doi.org/10.4161/onci.23639
   PubMedGoogle Scholar
• Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: a historical perspective. Pharmacol Ther 2012; 136:334-42; PMID:22940266; http://dx.doi.org/10.1016/j.pharmthera.2012.07.013
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 2011; 317:1255-60; PMID:21419116; http://dx.doi.org/10.1016/j.yexcr.2011.03.010
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493-8; PMID:21576633; http://dx.doi.org/10.1200/JCO.2010.32.7270
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, Neumann SA, Horst HA, Raff T, Viardot A et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012; 120:5185-7; PMID:23024237; http://dx.doi.org/10.1182/blood-2012-07-441030
   PubMed Web of Science ®Google Scholar
• Walter RB. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia. Expert Rev Hematol 2014; 7:317-9; PMID:24617311; http://dx.doi.org/10.1586/17474086.2014.896190
   PubMed Web of Science ®Google Scholar
• Rossi JF, Negrier S, James ND, Kocak I, Hawkins R, Davis H, Prabhakar U, Qin X, Mulders P, Berns B. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 2010; 103:1154-62; PMID:20808314; http://dx.doi.org/10.1038/sj.bjc.6605872
   PubMed Web of Science ®Google Scholar
• Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H et al. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 2011; 152:579-92; PMID:21241278; http://dx.doi.org/10.1111/j.1365-2141.2010.08533.x
   PubMed Web of Science ®Google Scholar
• Liu YC, Stone K, van Rhee F. Siltuximab for multicentric Castleman disease. Expert Rev Hematol 2014; 7:545-57; PMID:25110138; http://dx.doi.org/10.1586/17474086.2014.946402
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013; 19:3659-70; PMID:23659971; http://dx.doi.org/10.1158/1078-0432.CCR-12-3349
   PubMed Web of Science ®Google Scholar
• van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010; 28:3701-8; PMID:20625121; http://dx.doi.org/10.1200/JCO.2009.27.2377
   PubMed Web of Science ®Google Scholar
• van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, Simpson D, Capra M, Liu T, Hsieh RK et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2014; 15:966-74; PMID:25042199; http://dx.doi.org/10.1016/S1470-2045(14)70319-5
   PubMed Web of Science ®Google Scholar
• Krupitskaya Y, Wakelee HA. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 2009; 10:597-605; PMID:19513949
   PubMed Web of Science ®Google Scholar
• Shah MA. Gastrointestinal cancer: targeted therapies in gastric cancer-the dawn of a new era. Nat Rev Clin Oncol 2014; 11:10-11; PMID:24300880; http://dx.doi.org/10.1038/nrclinonc.2013.231
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383:31-9; PMID:24094768; http://dx.doi.org/10.1016/S0140-6736(13)61719-5
   PubMed Web of Science ®Google Scholar
• Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15:1224-35; PMID:25240821; http://dx.doi.org/10.1016/S1470-2045(14)70420-6
   PubMed Web of Science ®Google Scholar
• Owen C, Stewart DA. Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opin Biol Ther 2012; 12:343-51; PMID:22283718; http://dx.doi.org/10.1517/14712598.2012.657622
   PubMed Web of Science ®Google Scholar
• Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, Golay J. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011; 186:3762-9; PMID:21296976; http://dx.doi.org/10.4049/jimmunol.1000303
   PubMed Web of Science ®Google Scholar
• Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 2009; 10:588-96; PMID:19513948
   PubMed Web of Science ®Google Scholar
• Lee HZ, Miller BW, Kwitkowski VE, Ricci S, DelValle P, Saber H, Grillo J, Bullock J, Florian J, Mehrotra N et al. U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia. Clin Cancer Res 2014; 20:3902-7; PMID:24824310; http://dx.doi.org/10.1158/1078-0432.CCR-14-0516
   PubMed Web of Science ®Google Scholar
• Rai KR, Barrientos JC. Movement toward optimization of CLL therapy. N Engl J Med 2014; 370:1160-2; PMID:24645950; http://dx.doi.org/10.1056/NEJMe1400599
   PubMedGoogle Scholar
• Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370:1101-10; PMID:24401022; http://dx.doi.org/10.1056/NEJMoa1313984
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42; PMID:15175435; http://dx.doi.org/10.1056/NEJMoa032691
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50; PMID:17167137; http://dx.doi.org/10.1056/NEJMoa061884
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Nevala WK, Lieser EA, Leontovich AA, Markovic SN. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. Oncoimmunology 2013; 2:e24436; PMID:23762809; http://dx.doi.org/10.4161/onci.24436
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008; 68:5301-8; PMID:18593931; http://dx.doi.org/10.1158/0008-5472.CAN-08-0237
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vitale I, Martins I, Kepp O, Galluzzi L, Zitvogel L, Castedo M, Kroemer G. An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells. Oncoimmunology 2013; 2:e22409; PMID:23482968; http://dx.doi.org/10.4161/onci.22409
   PubMed Web of Science ®Google Scholar
• Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011; 12:385-92; PMID:21527953; http://dx.doi.org/10.1038/nrm3115
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014; 370:734-43; PMID:24552320; http://dx.doi.org/10.1056/NEJMoa1309748
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28:1749-55; PMID:20194866; http://dx.doi.org/10.1200/JCO.2009.25.3187
   PubMed Web of Science ®Google Scholar
• Keating MJ, Dritselis A, Yasothan U, Kirkpatrick P. Ofatumumab. Nat Rev Drug Discov 2010; 9:101-2; PMID:20118960; http://dx.doi.org/10.1038/nrd3100
   PubMed Web of Science ®Google Scholar
• Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, McDougal A, Pilaro A, Chiang R, Gootenberg JE et al. U.S. food and drug administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res 2010; 16:433-18; PMID:20601446; http://dx.doi.org/10.1158/1078-0432.CCR-10-0570
   PubMedGoogle Scholar
• Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, Klingemann H. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology 2013; 2:e26527; PMID:24404423; http://dx.doi.org/10.4161/onci.26527
   PubMed Web of Science ®Google Scholar
• Foa R. Changes in the treatment landscape for chronic lymphoid leukemia. N Engl J Med 2014; 371:273-4; PMID:25014693; http://dx.doi.org/10.1056/NEJMe1405766
   PubMedGoogle Scholar
• Hillmen P, Robak T, Janssens A, Govindbabu K, Grosicki S, Mayer J et al. Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911). ASH Meeting Abstr 2013:528; Available: https://ash.confex.com/ash/2013/webprogram/Paper58498.html
   Google Scholar
• Menger L, Vacchelli E, Kepp O, Eggermont A, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: cardiac glycosides and cancer therapy. Oncoimmunology 2013; 2:e23082; PMID:23525565; http://dx.doi.org/10.4161/onci.23082
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013; 2:e23803; PMID:23734328; http://dx.doi.org/10.4161/onci.23803
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013; 2:e24238; PMID:23762803; http://dx.doi.org/10.4161/onci.24238
   PubMed Web of Science ®Google Scholar
• Krishnan C, Warnke RA, Arber DA, Natkunam Y. PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis. Am J Surg Pathol 2010; 34:178-89; PMID:20087161; http://dx.doi.org/10.1097/PAS.0b013e3181cc7e79
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Erdmann MK. Immunity unleashed in melanoma. Lancet Oncol 2010; 11:108-9; PMID:20152761; http://dx.doi.org/10.1016/S1470-2045(09)70400-0
   PubMedGoogle Scholar
• Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-64; PMID:20004617; http://dx.doi.org/10.1016/S1470-2045(09)70334-1
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384:1109-17; PMID:25034862; http://dx.doi.org/10.1016/S0140-6736(14)60958-2
   PubMed Web of Science ®Google Scholar
• Ribas A, Hodi FS, Kefford R, Hamid O, Daud A, Wolchok JD et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). ASCO Meeting Abstr 2014; 32:LBA9000; Available: http://meetinglibrary.asco.org/content/133842-144
   Google Scholar
• Linch SN, Redmond WL. Combined OX40 ligation plus CTLA-4 blockade: more than the sum of its parts. Oncoimmunology 2014; 3:e28245; PMID:25050194; http://dx.doi.org/10.4161/onci.28245
   PubMed Web of Science ®Google Scholar
• Calabro L, Maio M. Immune checkpoint blockade in malignant mesothelioma: a novel therapeutic strategy against a deadly disease? Oncoimmunology 2014; 3:e27482; PMID:24734215; http://dx.doi.org/10.4161/onci.27482
   PubMedGoogle Scholar
• Robert L, Harview C, Emerson R, Wang X, Mok S, Homet B, Comin-Anduix B, Koya RC, Robins H, Tumeh PC et al. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology 2014; 3:e29244; PMID:25083336; http://dx.doi.org/10.4161/onci.29244
   PubMed Web of Science ®Google Scholar
• Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract 1998; 6:195-7; PMID:9652253; http://dx.doi.org/10.1046/j.1523-5394.1998.006003195.x
   PubMedGoogle Scholar
• Jones B. Haematological cancer: rituximab maintenance improves the outcome of elderly patients with FL. Nat Rev Clin Oncol 2013; 10:607; PMID:23999211; http://dx.doi.org/10.1038/nrclinonc.2013.164
   PubMedGoogle Scholar
• El-Osta HE, Kurzrock R. Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist 2011; 16:497-511; PMID:21441298; http://dx.doi.org/10.1634/theoncologist.2010-0212
   PubMed Web of Science ®Google Scholar
• Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384:665-73; PMID:24933332; http://dx.doi.org/10.1016/S0140-6736(14)60845-X
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369:32-42; PMID:23782158; http://dx.doi.org/10.1056/NEJMoa1215637
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369:507-16; PMID:23782157; http://dx.doi.org/10.1056/NEJMoa1306220
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371:213-23; PMID:24881631; http://dx.doi.org/10.1056/NEJMoa1400376
   PubMed Web of Science ®Google Scholar
• Kim ES, Neubauer M, Cohn A, Schwartzberg L, Garbo L, Caton J, Robert F, Reynolds C, Katz T, Chittoor S et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol 2013; 14:1326-36; PMID:24231627; http://dx.doi.org/10.1016/S1470-2045(13)70473-X
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32:1302-8; PMID:24637997; http://dx.doi.org/10.1200/JCO.2013.51.4489
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15:1269-78; PMID:25273342; http://dx.doi.org/10.1016/S1470-2045(14)70439-5
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15:747-56; PMID:24794243; http://dx.doi.org/10.1016/S1470-2045(14)70160-3
   PubMed Web of Science ®Google Scholar
• Navid F, Sondel PM, Barfield R, Shulkin BL, Kaufman RA, Allay JA, Gan J, Hutson P, Seo S, Kim K et al. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol 2014; 32:1445-52; PMID:24711551; http://dx.doi.org/10.1200/JCO.2013.50.4423
   PubMed Web of Science ®Google Scholar
• Desnoyers LR, Vasiljeva O, Richardson JH, Yang A, Menendez EE, Liang TW, Wong C, Bessette PH, Kamath K, Moore SJ et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci Transl Med 2013; 5:207ra144; PMID:24132639; http://dx.doi.org/10.1126/scitranslmed.3006682
   PubMed Web of Science ®Google Scholar
• Spring BQ, Abu-Yousif AO, Palanisami A, Rizvi I, Zheng X, Mai Z, Anbil S, Sears RB, Mensah LB, Goldschmidt R et al. Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates. Proc Natl Acad Sci U S A 2014; 111:E933-42; PMID:24572574; http://dx.doi.org/10.1073/pnas.1319493111
   PubMedGoogle Scholar
• Pearce OM, Laubli H, Verhagen A, Secrest P, Zhang J, Varki NM, Crocker PR, Bui JD, Varki A. Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proc Natl Acad Sci U S A 2014; 111:5998-6003; PMID:24711415; http://dx.doi.org/10.1073/pnas.1209067111
   PubMed Web of Science ®Google Scholar
• Gul N, Babes L, Siegmund K, Korthouwer R, Bogels M, Braster R, Vidarsson G, ten Hagen TL, Kubes P, van Egmond M. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest 2014; 124:812-23; PMID:24430180; http://dx.doi.org/10.1172/JCI66776
   PubMed Web of Science ®Google Scholar
• Montalvao F, Garcia Z, Celli S, Breart B, Deguine J, Van Rooijen N, Bousso P. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J Clin Invest 2013; 123:5098-103; PMID:24177426; http://dx.doi.org/10.1172/JCI70972
   PubMed Web of Science ®Google Scholar
• Li B, Meng Y, Zheng L, Zhang X, Tong Q, Tan W, Hu S, Li H, Chen Y, Song J et al. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization. Cancer Res 2013; 73:6471-83; PMID:24046294; http://dx.doi.org/10.1158/0008-5472.CAN-13-0657
   PubMed Web of Science ®Google Scholar
• Rossig C. Extending the chimeric receptor-based T-cell targeting strategy to solid tumors. Oncoimmunology 2013; 2:e26091; PMID:24244901; http://dx.doi.org/10.4161/onci.26091
   PubMedGoogle Scholar
• Kudo K, Imai C, Lorenzini P, Kamiya T, Kono K, Davidoff AM, Chng WJ, Campana D. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res 2014; 74:93-103; PMID:24197131; http://dx.doi.org/10.1158/0008-5472.CAN-13-1365
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 2014; 124:2668-82; PMID:24837434; http://dx.doi.org/10.1172/JCI73014
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, Fuseri N, Bonnafous C, Czerwinski D, Rajapaksa A et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 2014; 123:678-86; PMID:24326534; http://dx.doi.org/10.1182/blood-2013-08-519199
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov 2013; 12:829-46; PMID:24113830; http://dx.doi.org/10.1038/nrd4145
   PubMed Web of Science ®Google Scholar
• Husain Z, Seth P, Sukhatme VP. Tumor-derived lactate and myeloid-derived suppressor cells: linking metabolism to cancer immunology. Oncoimmunology 2013; 2:e26383; PMID:24404426; http://dx.doi.org/10.4161/onci.26383
   PubMed Web of Science ®Google Scholar
• Gondi G, Mysliwietz J, Hulikova A, Jen JP, Swietach P, Kremmer E, Zeidler R. Antitumor efficacy of a monoclonal antibody that inhibits the activity of cancer-associated carbonic anhydrase XII. Cancer Res 2013; 73:6494-503; PMID:24030978; http://dx.doi.org/10.1158/0008-5472.CAN-13-1110
   PubMed Web of Science ®Google Scholar
• Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D et al. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res 2013; 73:6024-35; PMID:23928993; http://dx.doi.org/10.1158/0008-5472.CAN-13-1198
   PubMed Web of Science ®Google Scholar
• Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110alpha inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer Res 2013; 73:6013-23; PMID:23918797; http://dx.doi.org/10.1158/0008-5472.CAN-13-1191
   PubMed Web of Science ®Google Scholar
• Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H et al. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal 2014; 7:ra29; PMID:24667376; http://dx.doi.org/10.1126/scisignal.2005125
   PubMed Web of Science ®Google Scholar
• Breij EC, de Goeij BE, Verploegen S, Schuurhuis DH, Amirkhosravi A, Francis J, Miller VB, Houtkamp M, Bleeker WK, Satijn D et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res 2014; 74:1214-26; PMID:24371232; http://dx.doi.org/10.1158/0008-5472.CAN-13-2440
   PubMed Web of Science ®Google Scholar
• Graves JD, Kordich JJ, Huang TH, Piasecki J, Bush TL, Sullivan T, Foltz IN, Chang W, Douangpanya H, Dang T et al. Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer Cell 2014; 26:177-89; PMID:25043603; http://dx.doi.org/10.1016/j.ccr.2014.04.028
   PubMed Web of Science ®Google Scholar
• Klitgaard JL, Koefoed K, Geisler C, Gadeberg OV, Frank DA, Petersen J, Pedersen MW. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells. Br J Haematol 2013; 163:182-93; PMID:23927424
   PubMed Web of Science ®Google Scholar
• Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang BE, Li Y, Mathieu M, Li G et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res 2014; 74:5561-71; PMID:25228655; http://dx.doi.org/10.1158/0008-5472.CAN-13-3622-T
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303-12; PMID:23177514; http://dx.doi.org/10.1016/S0140-6736(12)61900-X
   PubMed Web of Science ®Google Scholar
• Eisen T, Joensuu H, Nathan PD, Harper PG, Wojtukiewicz MZ, Nicholson S, Bahl A, Tomczak P, Pyrhonen S, Fife K et al. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol 2012; 13:1055-62; PMID:22959186; http://dx.doi.org/10.1016/S1470-2045(12)70364-9
   PubMed Web of Science ®Google Scholar
• Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13:528-38; PMID:22452896; http://dx.doi.org/10.1016/S1470-2045(12)70087-6
   PubMed Web of Science ®Google Scholar
• Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012; 13:539-48; PMID:22452895; http://dx.doi.org/10.1016/S1470-2045(12)70086-4
   PubMed Web of Science ®Google Scholar
• Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM, Soefje SA. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract 2014; Available: http://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+evaluation+of+compounds+targeting+PD-1%2FPD-L1+pathway+for+cancer+immunotherapy; PMID:24917416
   PubMedGoogle Scholar
• Langer CJ. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Am J Clin Oncol 2014; Available: http://www.ncbi.nlm.nih.gov/pubmed/?term=Emerging+Immunotherapies+in+the+Treatment+of+Non-Small+Cell+Lung+Cancer+(NSCLC)%3A+The+Role+of+Immune+Checkpoint+Inhibitors; PMID:24685885
   PubMedGoogle Scholar
• Creelan BC. Update on immune checkpoint inhibitors in lung cancer. Cancer Control 2014; 21:80-9; PMID:24357746
   PubMed Web of Science ®Google Scholar
• Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, Degryse S, Canté-Barrett K, Briot D, Clappier E et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood 2014; 124(25):3738-47; PMID:25301704; http://dx.doi.org/10.1182/blood-2014-05-574566
   PubMedGoogle Scholar
• ABT-199 Shows Effectiveness in CLL. Cancer Discov 2014; 4:OF7; http://dx.doi.org/10.1158/2159-8290.CD-NB2014-102
   Google Scholar
• Anderson MA, Huang D, Roberts A. Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol 2014; 51:219-27; PMID:25048785; http://dx.doi.org/10.1053/j.seminhematol.2014.05.008
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14:1208-15; PMID:24120480; http://dx.doi.org/10.1016/S1470-2045(13)70447-9
   PubMed Web of Science ®Google Scholar
• Yadav V, Burke TF, Huber L, Van Horn RD, Zhang Y, Buchanan SG, Chan EM, Starling JJ, Beckmann RP, Peng SB. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther 2014; 13:2253-63; PMID:25122067; http://dx.doi.org/10.1158/1535-7163.MCT-14-0257
   PubMed Web of Science ®Google Scholar
• Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Lallena MJ, Torres R, Ajamie RT, Wishart GN et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs 2014; 32:825-37; PMID:24919854; http://dx.doi.org/10.1007/s10637-014-0120-7
   PubMed Web of Science ®Google Scholar
• Uppenkamp M, Engert A, Diehl V, Bunjes D, Huhn D, Brittinger G. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. Ann Hematol 2002; 81:26-32; PMID:11807632; http://dx.doi.org/10.1007/s00277-001-0394-7
   PubMed Web of Science ®Google Scholar
• Schmitt B, Wendtner CM, Bergmann M, Busch R, Franke A, Pasold R, Schlag R, Hopfinger G, Hiddemann W, Emmerich B et al. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Clin Lymphoma 2002; 3:26-35; PMID:12141952; http://dx.doi.org/10.3816/CLM.2002.n.008
   PubMedGoogle Scholar
• Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov 2012; 11:19-20; PMID:22212672; http://dx.doi.org/10.1038/nrd3629
   PubMed Web of Science ®Google Scholar
• Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012; 30:631-7; PMID:22781692; http://dx.doi.org/10.1038/nbt.2289
   PubMed Web of Science ®Google Scholar
• Lainey E, Wolfromm A, Marie N, Enot D, Scoazec M, Bouteloup C, Leroy C, Micol JB, De Botton S, Galluzzi L et al. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. Oncogene 2013; 32:4331-42; PMID:23085751; http://dx.doi.org/10.1038/onc.2012.469
   PubMed Web of Science ®Google Scholar
• Thepot S, Lainey E, Cluzeau T, Sebert M, Leroy C, Ades L, Tailler M, Galluzzi L, Baran-Marszak F, Roudot H et al. Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Cell Cycle 2011; 10:2323-30; PMID:21654193; http://dx.doi.org/10.4161/cc.10.14.16399
   PubMed Web of Science ®Google Scholar
• Sand KE, Rye KP, Mannsaker B, Bruserud O, Kittang AO. Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients. Oncoimmunology 2013; 2:e23138; PMID:23525654; http://dx.doi.org/10.4161/onci.23138
   PubMedGoogle Scholar
• Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: lenalidomide-based immunochemotherapy. Oncoimmunology 2013; 2:e26494; PMID:24482747; http://dx.doi.org/10.4161/onci.26494
   PubMed Web of Science ®Google Scholar
• Semeraro M, Galluzzi L. Novel insights into the mechanism of action of lenalidomide. Oncoimmunology 2014; 3:e28386; PMID:25340011; http://dx.doi.org/10.4161/onci.28386
   PubMed Web of Science ®Google Scholar
• Giusti RM, Shastri K, Pilaro AM, Fuchs C, Cordoba-Rodriguez R, Koti K, Rothmann M, Men AY, Zhao H, Hughes M et al. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 2008; 14:1296-302; PMID:18316547; http://dx.doi.org/10.1158/1078-0432.CCR-07-1354
   PubMed Web of Science ®Google Scholar
• Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27:672-80; PMID:19114685; http://dx.doi.org/10.1200/JCO.2008.19.8135
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-34; PMID:18316791; http://dx.doi.org/10.1200/JCO.2007.14.7116
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109-19; PMID:22149875; http://dx.doi.org/10.1056/NEJMoa1113216
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13:25-32; PMID:22153890; http://dx.doi.org/10.1016/S1470-2045(11)70336-9
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31:1869-83; PMID:21892204; http://dx.doi.org/10.1038/onc.2011.384
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, Goubar A, Martins I, Michels J, Kratassiouk G et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep 2012; 2:257-69; PMID:22854025; http://dx.doi.org/10.1016/j.celrep.2012.06.017
   PubMed Web of Science ®Google Scholar
• Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013; 14:901-8; PMID:23867211; http://dx.doi.org/10.1016/S1470-2045(13)70277-8
   PubMed Web of Science ®Google Scholar
• Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, Jun S, Jacobs I. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012; 18:4415-24; PMID:22711702; http://dx.doi.org/10.1158/1078-0432.CCR-12-0578
   PubMed Web of Science ®Google Scholar
• Coleman RE. Bone cancer in 2011: prevention and treatment of bone metastases. Nat Rev Clin Oncol 2012; 9:76-8; PMID:22182971; http://dx.doi.org/10.1038/nrclinonc.2011.198
   PubMedGoogle Scholar
• Shaw NJ, Boivin CM, Crabtree NJ. Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child 2000; 83:143-5; PMID:10906023; http://dx.doi.org/10.1136/adc.83.2.143
   PubMedGoogle Scholar
• Peretz A, Body JJ, Dumon JC, Rozenberg S, Hotimski A, Praet JP, Moris M, Ham H, Bergmann P. Cyclical pamidronate infusions in postmenopausal osteoporosis. Maturitas 1996; 25:69-75; PMID:8887311; http://dx.doi.org/10.1016/0378-5122(96)01118-8
   PubMed Web of Science ®Google Scholar
• de Vetten MP, Jansen JH, van der Reijden BA, Berger MS, Zijlmans JM, Lowenberg B. Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676). Br J Haematol 2000; 111:277-9; PMID:11091212; http://dx.doi.org/10.1046/j.1365-2141.2000.02402.x
   PubMedGoogle Scholar
• Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19:3244-54; PMID:11432892
   PubMed Web of Science ®Google Scholar
• Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7:1490-6; PMID:11410481
   PubMed Web of Science ®Google Scholar
• McAleese F, Eser M. RECRUIT-TandAbs: harnessing the immune system to kill cancer cells. Future Oncol 2012; 8:687-95; PMID:22764766; http://dx.doi.org/10.2217/fon.12.54
   PubMed Web of Science ®Google Scholar
• Zhukovsky E, Reusch U, Burkhardt C, Knackmuss S, Fucek I, Eser M et al. AFM11, a CD19/CD3 bispecific tandab, to facilitate T-cell-mediated killing of CD19+ cells. ASCO Meeting Abstr 2013; 31:3068. Available: http://meetinglibrary.asco.org/content/115108-132
   Google Scholar
• Zhukovsky E, Knackmuss S, Reusch U, Wall C, Ellwanger K, Fucek I et al. Preclinical development, primary and secondary phrmacodynamics, of the CD19/CD3 Tandab (AFM11). ASCO Meeting Abstr 2014; 32:e19546. Available: http://meetinglibrary.asco.org/content/133329-144
   Google Scholar
• Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K et al. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 2008; 98:749-55; PMID:18253126; http://dx.doi.org/10.1038/sj.bjc.6604222
   PubMed Web of Science ®Google Scholar
• Casaco A, Lopez G, Garcia I, Rodriguez JA, Fernandez R, Figueredo J, Torres L, Perera A, Batista J, Leyva R et al. Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma. Cancer Biol Ther 2008; 7:333-9; PMID:18094616; http://dx.doi.org/10.4161/cbt.7.3.5414
   PubMed Web of Science ®Google Scholar
• Bebb G, Smith C, Rorke S, Boland W, Nicacio L, Sukhoo R, Brade A. Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother Pharmacol 2011; 67:837-45; PMID:20563810; http://dx.doi.org/10.1007/s00280-010-1379-9
   PubMed Web of Science ®Google Scholar
• Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010; 16:699-710; PMID:20068101; http://dx.doi.org/10.1158/1078-0432.CCR-09-1365
   PubMed Web of Science ®Google Scholar
• Jun HT, Sun J, Rex K, Radinsky R, Kendall R, Coxon A, Burgess TL. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007; 13:6735-42; PMID:18006775; http://dx.doi.org/10.1158/1078-0432.CCR-06-2969
   PubMed Web of Science ®Google Scholar
• Kakkar T, Ma M, Zhuang Y, Patton A, Hu Z, Mounho B. Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys. Pharm Res 2007; 24:1910-8; PMID:17520181; http://dx.doi.org/10.1007/s11095-007-9316-2
   PubMed Web of Science ®Google Scholar
• Lainey E, Sebert M, Thepot S, Scoazec M, Bouteloup C, Leroy C, De Botton S, Galluzzi L, Fenaux P, Kroemer G. Erlotinib antagonizes ABC transporters in acute myeloid leukemia. Cell Cycle 2012; 11:4079-92; PMID:23095522; http://dx.doi.org/10.4161/cc.22382
   PubMed Web of Science ®Google Scholar
• Boehrer S, Ades L, Braun T, Galluzzi L, Grosjean J, Fabre C, Le Roux G, Gardin C, Martin A, de Botton S et al. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2008; 111:2170-80; PMID:17925489; http://dx.doi.org/10.1182/blood-2007-07-100362
   PubMed Web of Science ®Google Scholar
• Le Garff-Tavernier M, Herbi L, de Romeuf C, Nguyen-Khac F, Davi F, Grelier A, Boudjoghra M, Maloum K, Choquet S, Urbain R et al. Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. Leukemia 2014; 28:230-3; PMID:23958919; http://dx.doi.org/10.1038/leu.2013.240
   PubMedGoogle Scholar
• Ben Abdelwahed R, Donnou S, Ouakrim H, Crozet L, Cosette J, Jacquet A, Tourais I, Fournès B, Gillard Bocquet M, Miloudi A et al. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas. Invest Ophthalmol Vis Sci 2013; 54:3657-65; PMID:23611989; http://dx.doi.org/10.1167/iovs.12-10316
   PubMedGoogle Scholar
• Liu L, Zeng W, Wortinger MA, Yan SC, Cornwell PD, Peek VL, Stephens JR, Tetreault JW, Xia J, Manro JR et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res 2014; 20:6059-70; PMID:25231402; http://dx.doi.org/10.1158/1078-0432.CCR-14-0543
   PubMed Web of Science ®Google Scholar
• Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 2009; 114:2721-9; PMID:19633198; http://dx.doi.org/10.1182/blood-2009-02-205500
   PubMed Web of Science ®Google Scholar
• Polson AG, Yu SF, Elkins K, Zheng B, Clark S, Ingle GS, Slaga DS, Giere L, Du C, Tan C et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood 2007; 110:616-23; PMID:17374736; http://dx.doi.org/10.1182/blood-2007-01-066704
   PubMed Web of Science ®Google Scholar
• Tageja N, Nagi J. Bendamustine: something old, something new. Cancer Chemother Pharmacol 2010; 66:413-23; PMID:20376452; http://dx.doi.org/10.1007/s00280-010-1317-x
   PubMed Web of Science ®Google Scholar
• Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, Legha S, Ross MI, Thompson L, Mujoo K et al. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol 1996; 19:206-17; PMID:8811495; http://dx.doi.org/10.1097/00002371-199605000-00005
   PubMed Web of Science ®Google Scholar
• Ozkaynak MF, Sondel PM, Krailo MD, Gan J, Javorsky B, Reisfeld RA, Matthay KK, Reaman GH, Seeger RC. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 2000; 18:4077-85; PMID:11118469
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-34; PMID:20879881; http://dx.doi.org/10.1056/NEJMoa0911123
   PubMed Web of Science ®Google Scholar
• Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Klingebiel T, Berthold F. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer 2011; 11:21; PMID:21244693; http://dx.doi.org/10.1186/1471-2407-11-21
   PubMed Web of Science ®Google Scholar
• Modak S, Kushner BH, Kramer K, Vickers A, Cheung IY, Cheung NK. Anti-GD2 antibody 3F8 and barley-derived (1 -> 3),(1 -> 4)-beta-glucan: a phase I study in patients with chemoresistant neuroblastoma. Oncoimmunology 2013; 2:e23402; PMID:23802080
   PubMed Web of Science ®Google Scholar
• Cheung NK, Guo H, Hu J, Tassev DV, Cheung IY. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology 2012; 1:477-86; PMID:22754766; http://dx.doi.org/10.4161/onci.19864
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory cytokines. Oncoimmunology 2013; 2:e24850; PMID:24073369; http://dx.doi.org/10.4161/onci.24850
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014; 3:e29030; PMID:25083328; http://dx.doi.org/10.4161/onci.29030
   PubMed Web of Science ®Google Scholar
• Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, Hunter JH, Leiske CI, Miyamoto JB, Nicholas ND et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem 2013; 24:1256-63; PMID:23808985; http://dx.doi.org/10.1021/bc400217g
   PubMed Web of Science ®Google Scholar
• Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, Farsaci B, Donahue R, Gulley JL, Schlom J et al. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology 2013; 2:e27025; PMID:24353914; http://dx.doi.org/10.4161/onci.27025
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28:3239-47; PMID:20498403; http://dx.doi.org/10.1200/JCO.2008.21.6457
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28-37; PMID:22720209; http://dx.doi.org/10.4161/onci.1.1.17938
   PubMed Web of Science ®Google Scholar
• Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, Belmontes B, Ho J, Tsai MM, Zhu M, Vonderfecht S et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 2009; 8:1095-105; PMID:19366899; http://dx.doi.org/10.1158/1535-7163.MCT-08-1171
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2:e23510; PMID:23687621; http://dx.doi.org/10.4161/onci.23510
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30:2190-6; PMID:22614995; http://dx.doi.org/10.1200/JCO.2011.38.0402
   PubMed Web of Science ®Google Scholar
• McKian KP, Haluska P. Cixutumumab. Expert Opin Investig Drugs 2009; 18:1025-33; PMID:19548856; http://dx.doi.org/10.1517/13543780903055049
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Rivera F, Maurel J, Ayoub J-PM, Moore MJ, Cervantes-Ruiperez A, Asmis TR, Schwartz JD, Nasroulah F, Ballal S et al. A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784. ASCO Meeting Abstracts 2012; 30:533; PMID:24674871; http://dx.doi.org/10.1634/theoncologist.2014-0028
   PubMedGoogle Scholar
• Yoshino T, Yamazaki K, Yoshida M, Rutstein MD, Yoshizuka N, Ohtsu A. A phase (Ph) Ib study of irinotecan (IRI), levofolinate (LV), and 5-fluorouracil (5-FU) (FOLFIRI) plus ramucirumab (RAM; IMC-1121B) drug product in Japanese (JP) patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (CP12-1029/NCT01286818). ASCO Meeting Abstr 2013; 31:591.
   Google Scholar
• Towle MJ, Salvato KA, Wels BF, Aalfs KK, Zheng W, Seletsky BM, Zhu X, Lewis BM, Kishi Y, Yu MJ et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 2011; 71:496-505; PMID:21127197; http://dx.doi.org/10.1158/0008-5472.CAN-10-1874
   PubMed Web of Science ®Google Scholar
• Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004; 64:5760-6; PMID:15313917; http://dx.doi.org/10.1158/0008-5472.CAN-04-1169
   PubMed Web of Science ®Google Scholar
• Yardley DA, Richards PD, Reeves JA, Dees EC, Osborne CRC, Soliman HH et al. Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC). ASCO Meeting Abstr 2014; 32:1035. Available: http://meetinglibrary.asco.org/content/126127-144
   Google Scholar
• Stein MN, Chow LQM, Smith DC, Shepard DR, Wang D, Powderly JD et al. Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of docetaxel (DOC) in patients (pts) with advanced malignant solid tumors. ASCO Meeting Abstr 2014; 32:e13539.Available: http://meetinglibrary.asco.org/content/126489-144
   Google Scholar
• Shaughnessy AF. Monoclonal antibodies: magic bullets with a hefty price tag. BMJ 2012; 345:e8346; PMID:23236036; http://dx.doi.org/10.1136/bmj.e8346
   PubMed Web of Science ®Google Scholar
• Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Herve Fridman W, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2014; 3:e28185; PMID:24800178; http://dx.doi.org/10.4161/onci.28185
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2013; 2:e26621; PMID:24498550; http://dx.doi.org/10.4161/onci.26621
   PubMed Web of Science ®Google Scholar
• Reslan L, Dalle S, Dumontet C. Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs 2009; 1:222-9; PMID:20065642; http://dx.doi.org/10.4161/mabs.1.3.8292
   PubMed Web of Science ®Google Scholar
• Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol 2012; 22:3-13; PMID:22245472; http://dx.doi.org/10.1016/j.semcancer.2011.12.009
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236
   PubMed Web of Science ®Google Scholar
• Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010; 9:325-38; PMID:20305665; http://dx.doi.org/10.1038/nrd3003
   PubMed Web of Science ®Google Scholar